MasupirdineMasupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Sponsor:

Suven Life Sciences Limited

Code:

NCT05397639

Conditions

Agitation

Alzheimer's Type Dementia

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Not accepted

Interventions

Masupirdine 50 mg

Masupirdine 100 mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by Suven Life Sciences Limited on 2026-01-12.